Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589168 | 0.90 | LTA4H (0.55) | HRH3KCNH2LTA4HADRA1A | |
| SCHEMBL9968651 | 0.90 | HRH3 (0.54) | HRH3KCNH2LTA4HADRA1A | |
| Hydrochloric Acid SCHEMBL3588666 | 0.89 | HRH3 (0.53) | HRH3KCNH2LTA4HADRA1A | |
| SCHEMBL3600669 | 0.89 | HRH3 (0.55) | HRH3KCNH2LTA4HNPC1RAB9A | |
| SCHEMBL3598019 | 0.84 | HRH3 (0.53) | HRH3KCNH2LTA4HADRA1A | |
| SCHEMBL17842304 | 0.79 | NPC1 (0.70) | MAPTGALR3HRH3KCNH2LTA4H | |
| SCHEMBL3640202 | 0.76 | ACHE (0.51) | MAPTHRH3KCNH2LTA4HADRA1A | |
| SCHEMBL17842350 | 0.76 | NPC1 (0.68) | HRH3KCNH2LTA4HNPC1RAB9A | |
| SCHEMBL5072101 | 0.74 | TP53 (0.44) | MAPTNPC1RAB9A | |
| SCHEMBL3591758 | 0.74 | ESR2 (0.58) | HRH3KCNH2NPC1RAB9AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963276-B9 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-09-26 | — | — | EP | disclosed |
| EP-1963276-B9 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-09-26 | — | — | EP | disclosed |
| EP-1963276-B1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-06-20 | — | — | EP | disclosed |
| EP-1963276-B1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2012-06-20 | — | — | EP | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| US-7674802-B2 | leukotriene A4 hydrolase inhibitors; biaryl nitrogen-attached heterocycles | DECODE GENETICS, EHF (IS) | 2010-03-09 | — | — | US | disclosed |
| EP-1963276-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007073405-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007073405-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142434-A1 | N-LINKED ARYL HETEROARYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | MAPT 4521/4885GALR3 729/4885HRH3 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.